NSCLC ADVANCES Initiative

Lung cancer – the most deadly form of cancer, is responsible for more deaths than any form of cancer, with more than 130,180 deaths due to cancers of the lung and bronchus in 2021. The high death rate in lung cancer is partially attributable to the fact that more than half of patients (57%) are diagnosed when the disease has already metastasized. In recent years, several seminal studies have investigated immune checkpoint inhibitors (ICIs) for the management of non-small cell lung cancer (NSCLC), including studies of ICIs in later-line metastatic disease, first-line metastatic disease as monotherapy, first-line metastatic disease in combination with chemotherapy, and more recently in the locally advanced setting. Since 2001, overall survival associated in men with NSCLC lung cancer has improved by 26%. In those diagnosed with lung cancer after 2014, the improvement in overall survival has been even more dramatic, estimated at 35%. Incidence decreased by 6.3% yearly from 2013 to 2016. These improvements have been attributed in part to reductions in smoking and the developments in targeted therapies and checkpoint inhibitors for NSCLC.

Our ADVANCES website aims to provide clinicians as well as patients and caregivers with up-to-date information on the immunopathologic factors in the pathogenesis of NSCLC, the latest clinical trial updates concerning front-line use of immuno-oncology strategies in NSCLC, and management strategies for targeting NSCLC based on clinical biomarkers.

This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2024 Med Learning Group. Built by Divigner. All Rights Reserved.

Scientific Council

Neil M. Bressler, MD

James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

A. Paul Chous, MA, OD, FAAO

Specializing in Diabetes Eye Care & Education, Chous Eye Care Associates
Adjunct Professor of Optometry, Western University of Health Sciences
AOA Representative, National Diabetes Education Program
Tacoma, WA

Steven Ferrucci, OD, FAAO

Chief of Optometry, Sepulveda VA Medical Center
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Sepulveda, CA

Julia A. Haller, MD

Ophthalmologist-in-Chief
Wills Eye Hospital
Philadelphia, PA

Allen C. Ho, MD, FACS

Director, Retina Research
Wills Eye Hospital
Professor and Chair of the Department of Ophthalmology
Thomas Jefferson University Hospitals
Philadelphia, PA

Charles C. Wykoff, MD, PhD

Director of Research, Retina Consultants of Houston
Associate Professor of Clinical Ophthalmology
Blanton Eye Institute & Houston Methodist Hospital
Houston, TX

Search

[divi_global_search_form]

Clinician Scientific & Educational Resources

The RELIEF Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for retinopathy of prematurity (ROP). Click on one of the options below to learn more about ROP.

Patient Toolkit

Patient Toolkit

Read more

What exactly is NSCLC?

What exactly is NSCLC?

Read more

What symptoms can NSCLC cause?

What symptoms can NSCLC cause?

Read more

How is NSCLC treated according to staging?

How is NSCLC treated according to staging?

Read more

How is early NSCLC treated with surgery or SBRT?

How is early NSCLC treated with surgery or SBRT?

Read more

When is chemotherapy used in NSCLC?

When is chemotherapy used in NSCLC?

Read more

When is radiation used in NSCLC?

When is radiation used in NSCLC?

Read more

When is immunotherapy used in NSCLC?

When is immunotherapy used in NSCLC?

Read more

When is targeted therapy used in NSCLC?

When is targeted therapy used in NSCLC?

Read more

Online resources

Online resources

Read more
This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM). This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2019 | ROP Relief | All Rights Reserved | Website by Divigner